Cipla Ltd — Q4 FY26 earnings call
Summary generated by AI from the official transcript Cipla Ltd filed with BSE on 15 May 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
Cipla reported Q4 FY26 revenue of Rs 6,541 crore and full year revenue of Rs 28,163 crore, with EBITDA margin at 15.2% for the quarter and 21% for the year. One India crossed Rs 12,500 crore in annual revenue growing 15% year-on-year in the quarter, North America reported quarterly revenue of $155 million and annual revenue of $780 million, and management received U.S. FDA approval for a generic Ventolin product from its U.S. facility. Management guided FY27 EBITDA margins to a range of 18.5% to 20%, excluding any contribution from Lanreotide.
Numbers mentioned
Revenue: INR6,541 crores (Q4 FY26)
p. 6
“So we reported a quarterly revenue of INR6,541 crores.”
Ashish Adukia, page 6 of the filed PDF · View the filing
Revenue: INR 28,163 crores (FY26)
p. 6
“And as a result of that, we ended the year with INR 28,163 crores.”
Ashish Adukia, page 6 of the filed PDF · View the filing
EBITDA margin: 15.2% (Q4 FY26)
p. 6
“The EBITDA margins for the quarter stood at 15.2% and 21% for the year.”
Ashish Adukia, page 6 of the filed PDF · View the filing
Gross margin: 65.6% (Q4 FY26)
p. 6
“The gross margin after material costs stood at 65.6% for the quarter and 66% for the full year.”
Ashish Adukia, page 6 of the filed PDF · View the filing
One India revenue: INR12,500 crores (FY26)
p. 3
“In India, we crossed a significant threshold with the business surpassing INR12,500 crores in revenues, underscoring the strength and resilience of our domestic franchise, which is our largest franchise.”
Achin Gupta, page 3 of the filed PDF · View the filing
One India growth: 15% year-on-year (Q4 FY26)
p. 3
“Our One India business delivered a robust performance this quarter, growing at 15% year-on-year, driven by strong double-digit growth across Branded Prescription, Trade Generics as well as Consumer Health.”
Achin Gupta, page 3 of the filed PDF · View the filing
One India full year growth: 9% Y-o-Y (FY26)
p. 3
“Full year growth stands at 9% Y-o-Y.”
Achin Gupta, page 3 of the filed PDF · View the filing
North America revenue: USD 155 million (Q4 FY26)
p. 5
“Coming to North America, the business reported quarterly revenue of USD 155 million and an annual revenue of $780 million, supported by demand in our differentiated portfolio and a steady base business.”
Achin Gupta, page 5 of the filed PDF · View the filing
Albuterol market share: 19.6% (MAT March '26)
p. 5
“Albuterol market share increased to 19.6% as per IQVIA MAT March '26.”
Achin Gupta, page 5 of the filed PDF · View the filing
One Africa growth: 14% year-on-year (Q4 FY26)
p. 5
“Our One Africa business grew at an impressive 14% year-on-year growth rate during the quarter with a full year growth of 7% Y-o-Y in USD terms, powered by firm performance across key markets.”
Achin Gupta, page 5 of the filed PDF · View the filing
EMEU revenue: USD 400 million-plus (FY26)
p. 5
“In EMEU, our focused strategy on deep penetration has built a strong foundation, enabling the business to breach the USD 400 million revenue mark.”
Achin Gupta, page 5 of the filed PDF · View the filing
R&D spend: INR509 crores (Q4 FY26)
p. 6
“Overall, the operating expenses also include continued investment in R&D, which stood at INR509 crores, which is at about 7.8% of the revenue for the quarter.”
Ashish Adukia, page 6 of the filed PDF · View the filing
R&D spend: INR1,974 crores (FY26)
p. 6
“And for the year, it was INR1,974 crores, which is at about 7% of the revenue.”
Ashish Adukia, page 6 of the filed PDF · View the filing
PAT: INR 555 crores (Q4 FY26)
p. 7
“For the quarter, PAT stood at INR 555 crores, representing 8.5% of sales with an effective tax rate of 22.2%.”
Ashish Adukia, page 7 of the filed PDF · View the filing
PAT: INR3,879 crores (FY26)
p. 7
“On the full-year basis, the PAT amounts to INR3,879 crores, accounting to 13.8% of sales, while the ETR for the year is 25.9%.”
Ashish Adukia, page 7 of the filed PDF · View the filing
ROIC: 22.9% (FY26)
p. 7
“Our ROIC stood at 22.9% for the year.”
Ashish Adukia, page 7 of the filed PDF · View the filing
Net cash: INR10,526 crores (as of 31st March 2026)
p. 7
“As of 31st March 2026, the debt on our balance sheet, including the lease liabilities stood at INR 614 crores with net cash equivalent balance at INR10,526 crores.”
Ashish Adukia, page 7 of the filed PDF · View the filing
Foracort revenue: INR1,000 crores (FY26)
p. 3
“Foracort, our leading inhalation brand surpassed the revenue of INR1,000 crores, reaffirming its position as a respiratory market leader.”
Achin Gupta, page 3 of the filed PDF · View the filing
Dytor revenue growth: 25% Y-o-Y (FY26)
p. 4
“Meanwhile, Dytor, our cardiac brand, has established itself as a -- as a INR650 crores brand, delivering 25% Y-o-Y growth.”
Achin Gupta, page 4 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
EBITDA margin — 18.5% to 20% · FY27
stated firmly by Ashish Adukia
p. 7
“We expect the EBITDA margins to be in the range of 18.5% to 20% and this would be actually achieved with a sequential improvement quarter-on-quarter with the key improvement being in the second half of the year.”
Ashish Adukia, page 7 of the filed PDF · View the filing
North America revenue run rate — $1 billion · end of FY27
stated conditionally by Achin Gupta
p. 9
“So the guidance, I just wanted to clarify is a $1 billion run rate by the end of the year.”
Achin Gupta, page 9 of the filed PDF · View the filing
One India growth — strong double-digit growth · FY27, FY28
stated as an aspiration by Achin Gupta
p. 13
“Yes. So we are confident that we'll be able to deliver a strong double-digit growth as well as a market beating growth in FY '27, '28.”
Achin Gupta, page 13 of the filed PDF · View the filing
Lanreotide filing — file from alternate U.S. supplier · early next calendar year or Q4 of this financial year
stated conditionally by Achin Gupta
p. 10
“So the objective is to be able to file by early next year -- next calendar year or Q4 of this financial year.”
Achin Gupta, page 10 of the filed PDF · View the filing
Respiratory asset filings — 4 additional respiratory assets · next 24 months
stated firmly by Achin Gupta
p. 5
“We are also going to deepen this pipeline with 4 additional respiratory assets scheduled for filing over the next 24 months.”
Achin Gupta, page 5 of the filed PDF · View the filing
Green propellant respiratory assets — 2 respiratory assets · next 24 months
stated firmly by Achin Gupta
p. 5
“Importantly, we remain committed to sustainability and innovation with 2 respiratory assets incorporating green propellant expected to be filed over the next 24 months as well.”
Achin Gupta, page 5 of the filed PDF · View the filing
R&D spend as % of sales — 7%-ish, biased toward 7% · FY27
stated firmly by Ashish Adukia
p. 18
“R&D also, while it is discretionary and in hand, but still will continue to be at about 6% to 7%, but more biased towards 7% because we are increasing the number of programs, etcetera.”
Ashish Adukia, page 18 of the filed PDF · View the filing
EBITDA margin — 20 plus · FY28 and beyond
stated as an aspiration by Ashish Adukia
p. 18
“To be fair, I think it should 20 plus is something that we should anyway sustain going forward.”
Ashish Adukia, page 18 of the filed PDF · View the filing
Biosimilar pipeline — 6 to 8 in-house assets · next 5 to 8 years
stated as an aspiration by Achin Gupta
p. 9
“We will be adding 1 to 2 assets each year, which will then, therefore, start resulting into a pipeline of 6 to 8 in-house assets over the next 5 to 8 years.”
Achin Gupta, page 9 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Management said switching to another variant is not an automatic process under U.S. law, so no near-term impact is anticipated.
Answered by Achin Gupta
Asked by Vishal Manchanda: Whether the innovator's transition to a green Ventolin variant would impact Cipla's generic launch.
p. 8
“So we do not anticipate any near-term impact of that change as and when the transition starts to happen.”
Achin Gupta, page 8 of the filed PDF · View the filing
Management clarified it is a run-rate target by year end, not full-year revenue, contingent on pipeline approvals maturing through the year.
Answered by Achin Gupta
Asked by Surya Patra: What is driving the bridge to the $1 billion U.S. run rate guidance given Lanreotide and Lenalidomide are excluded.
p. 9
“We are not guiding for $1 billion revenue during the year, right? And the reason for that is because a lot of this is contingent on pipeline maturing.”
Achin Gupta, page 9 of the filed PDF · View the filing
Management said the partner is working on remediation and Cipla has also identified an alternate U.S.-based manufacturing site to file separately.
Answered by Achin Gupta
Asked by Surya Patra: What is the outlook for Lanreotide given the ongoing disruption.
p. 10
“So for Lanreotide, we have the partner who is working on the remediation efforts.”
Achin Gupta, page 10 of the filed PDF · View the filing
Management said the change was minor and attributed potential share gains to supply availability.
Answered by Ashish Adukia
Asked by Tushar Manudhane: Why has the Albuterol market share moved down from 22% to 19.5% quarter over quarter.
p. 11
“No. I think it's hardly a reduction that you see out there of 0.4% or so that we've seen.”
Ashish Adukia, page 11 of the filed PDF · View the filing
Management said a couple of products are expected to be $100 million-plus annualized opportunities, with a peptide asset also being significant, rather than reliance on just one product.
Answered by Achin Gupta
Asked by Nikhil Mathur: How skewed is the incremental $380 million of U.S. revenue across the pipeline products.
p. 15
“So Nikhil, in terms of annualized revenues from these products, I think a couple of them, we are expecting $100 million plus annualized opportunities, right?”
Achin Gupta, page 15 of the filed PDF · View the filing
Management confirmed H2 margins will be better than the 18.5-20% average while H1 will be below it.
Answered by Ashish Adukia
Asked by Neha Manpuria: Whether India margin guidance implies H2 margins will be meaningfully above the average range given U.S. launch timing.
p. 17
“Yes. So that's exactly what I had mentioned initially that in 18.5% to 20% that we're guiding, it will be more in the favor of H2 where you will have better than average and first 2 quarters where we don't have the benefit of new launches, we will see a lower margin than the average that we're giving.”
Ashish Adukia, page 17 of the filed PDF · View the filing
Management said sustained investment in people and R&D costs, along with a moderate geopolitical war risk, are factored into the guidance.
Answered by Ashish Adukia
Asked by Vivek Agarwal: Whether the FY27 margin guidance of 18.5-20% is conservative given the U.S. and India growth outlook.
p. 18
“So therefore, I think 18.5% to 20% is a fair margin to assume.”
Ashish Adukia, page 18 of the filed PDF · View the filing
Risks flagged
Geopolitical war-related disruption affecting sourcing and operating expenses
p. 6
“In addition, we have started to see some impact of ongoing geopolitical situation within the operating expenses, which we are closely monitoring.”
Ashish Adukia, page 6 of the filed PDF · View the filing
Future impact from war-related inventory costs as revenue inventory is consumed
p. 7
“In the near quarters, we don't see a meaningful impact. But in the future quarters as the revenue inventory gets consumed, you'll see that impact coming through.”
Ashish Adukia, page 7 of the filed PDF · View the filing
Lanreotide supply disruption at partner manufacturing site
p. 13
“Ventolin where we were expecting around the same time we've got the approval.”
Ashish Adukia, page 13 of the filed PDF · View the filing
Goa facility inspection observations pending classification
p. 13
“There are 2 observations we are waiting -- we have responded to those observations. We are waiting for the classification.”
Ashish Adukia, page 13 of the filed PDF · View the filing
Potential price erosion in U.S. products from new competition
p. 15
“So where we have to manage some level of price erosion, but not a cliff kind of scenario, right?”
Achin Gupta, page 15 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.